Sera Prognostics, Inc. (NASDAQ:SERA) Insider Sells $105,004.51 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider Robert Gardner Harrison sold 14,209 shares of the business’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $7.39, for a total value of $105,004.51. Following the completion of the sale, the insider now directly owns 116,837 shares of the company’s stock, valued at approximately $863,425.43. This represents a 10.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Robert Gardner Harrison also recently made the following trade(s):

• On Monday, January 13th, Robert Gardner Harrison sold 2,264 shares of Sera Prognostics stock. The shares were sold at an average price of $6.47, for a total value of $14,648.08.

Sera Prognostics Price Performance

Shares of SERA opened at $6.60 on Friday. Sera Prognostics, Inc. has a 12-month low of $4.98 and a 12-month high of $12.35. The business’s fifty day moving average price is $7.40 and its 200 day moving average price is $7.31. The stock has a market capitalization of $222.88 million, a PE ratio of -6.67 and a beta of 0.86.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.09 million. During the same period in the previous year, the business earned ($0.23) earnings per share. As a group, research analysts anticipate that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sera Prognostics

Several institutional investors have recently made changes to their positions in SERA. JPMorgan Chase & Co. boosted its position in Sera Prognostics by 7,357.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 884,867 shares of the company’s stock valued at $6,902,000 after purchasing an additional 873,002 shares during the period. Bank of New York Mellon Corp lifted its stake in Sera Prognostics by 100.2% in the second quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock valued at $892,000 after buying an additional 75,441 shares during the last quarter. Sanders Morris Harris LLC grew its position in shares of Sera Prognostics by 165.7% during the fourth quarter. Sanders Morris Harris LLC now owns 90,600 shares of the company’s stock worth $725,000 after acquiring an additional 56,500 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Sera Prognostics by 8.9% during the third quarter. Geode Capital Management LLC now owns 586,837 shares of the company’s stock worth $4,578,000 after acquiring an additional 47,969 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Sera Prognostics by 8.8% in the 3rd quarter. State Street Corp now owns 425,093 shares of the company’s stock worth $3,316,000 after acquiring an additional 34,479 shares during the period. 54.64% of the stock is owned by institutional investors.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.